Cellular Biomedicine Group (CBMG) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cellular Biomedicine Group Reports Third Quarter 2015 Financial Results and Provides Business Highlights
November 13, 2015 9:21 AM ESTSHANGHAI, China and CUPERTINO, Calif., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (CBMG or the Company), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today reported financial results for the quarter ended September 30, 2015 and provided business highlights.
Dr. William Wei Cao, Chief Executive Officer, commented, We achieved pivotal milestones in the third quarter that redefined CBMGs business and strategically positioned the Company as an emerging, bifurcated and world-class immuno-oncology and cell therapy contender with international aspirations through the... More
